Dovato Demonstrates Sustained HIV Control, Offers Weight Management Benefits Over Biktarvy
New data presented at IDWeek 2025 and in ongoing studies reveal that the two-drug regimen Dovato (dolutegravir/lamivudine) maintains robust viral suppression in people living with HIV, particularly older adults, and is associated with significantly less weight gain compared to the widely used three-drug therapy Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).
The Evolving Landscape of HIV Treatment
For decades, HIV treatment has relied on complex antiretroviral therapies (ART). While these regimens have dramatically improved the lives of people living with HIV, they often come with side effects, including weight gain, metabolic disturbances, and the burden of taking multiple pills daily. The pursuit of simpler, more tolerable, and equally effective treatment options remains a central focus in HIV research.
Dovato, approved by the FDA in 2019, represents a significant step towards this goal. As a two-drug regimen, it simplifies treatment and potentially reduces the risk of long-term toxicities associated with multi-drug therapies. However, questions remained regarding its efficacy across diverse patient populations and its impact on metabolic health.
PASO-DOBLE and Beyond: 96-Week Results
The 96-week results from the pivotal Phase 3 PASO-DOBLE trial, recently announced by ViiV Healthcare, provide compelling evidence supporting Dovato’s continued effectiveness. The study demonstrated that Dovato was non-inferior to Biktarvy in maintaining virological suppression – meaning the amount of HIV in the blood remained undetectable – in treatment-naive adults. BioSpace and Contagion Live reported on these findings.
Crucially, the study also revealed a statistically significant difference in weight gain between the two groups. Participants on Dovato experienced considerably less weight gain compared to those on Biktarvy, a finding that has significant implications for long-term health and quality of life.
Dovato in Older Adults: IDWeek 2025 Findings
Data presented at IDWeek 2025 further solidified Dovato’s efficacy in a specific population often underrepresented in clinical trials: older adults. Researchers found that Dovato, as well as regimens including bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and dolutegravir/lamivudine (DTG/3TC), demonstrated excellent virologic control in older individuals living with HIV. European AIDS Treatment Group detailed these results.
This is particularly encouraging given the increasing prevalence of HIV among older adults and the unique challenges they face, such as co-morbidities and age-related physiological changes.
What does this mean for the future of HIV treatment? Could simpler regimens like Dovato become the standard of care, reducing the burden on patients and improving long-term health outcomes? And how will these findings influence treatment decisions for older adults living with HIV?
ViiV Healthcare also announced promising 96-week results, reinforcing Dovato’s effectiveness and highlighting its advantages. Investing.com Canada and GuruFocus covered these developments.
Frequently Asked Questions About Dovato
What is Dovato and how does it work?
Dovato is a complete regimen, meaning it contains two medicines in one tablet, used to treat HIV-1 infection in certain adults. It combines dolutegravir and lamivudine, both of which are antiretroviral drugs that work by blocking the HIV virus from replicating in the body.
Is Dovato suitable for everyone with HIV?
No, Dovato is not appropriate for all individuals with HIV. It is generally prescribed for treatment-naive adults with no known resistance mutations to either dolutegravir or lamivudine. Your healthcare provider will determine if Dovato is the right option for you.
How does Dovato compare to Biktarvy in terms of efficacy?
Clinical trials, such as the PASO-DOBLE study, have shown that Dovato is non-inferior to Biktarvy in maintaining virological suppression in people with HIV. This means it is just as effective at controlling the virus.
What are the potential side effects of Dovato?
Common side effects of Dovato can include headache, nausea, and fatigue. Serious side effects are rare but can occur. It’s important to discuss any concerns with your doctor.
Does Dovato cause weight gain?
Studies indicate that Dovato is associated with significantly less weight gain compared to Biktarvy, which is a notable benefit for long-term health.
The continued development of innovative HIV treatments like Dovato offers hope for a future where managing HIV is simpler, more effective, and less burdensome for people living with the virus.
Keep reading
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.